NCT05881967

Brief Summary

The purpose of this project was to use multi-omics technology to screen the key factors for the occurrence and development of uterine sarcoma.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2023

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

May 21, 2023

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 31, 2023

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2025

Completed
Last Updated

May 31, 2023

Status Verified

May 1, 2023

Enrollment Period

2.8 years

First QC Date

May 21, 2023

Last Update Submit

May 21, 2023

Conditions

Uterine Sarcoma

Outcome Measures

Primary Outcomes (1)

  • Susceptible gene in women with uterine sarcoma

    Analyze genetic susceptibility among women exhibiting disease manifestations of uterine sarcoma

    baseline

Study Arms (2)

Uterine sarcoma

Participants were enrolled for the first treatment of uterine sarcoma or secondary operation for recurrence fo uterine sarcoma.

Diagnostic Test: Diagnostic biomarker

Uterine fibroid

Participants were enrolled for surgery of uterine fibroids.

Diagnostic Test: Diagnostic biomarker

Interventions

Diagnostic biomarkerDIAGNOSTIC_TEST

Diagnostic gene for uterine sarcoma

Uterine fibroidUterine sarcoma

Eligibility Criteria

Age18 Years - 99 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

400 patients who met the requirements includ 200 uterine sarcomas, 200 uterine leiomyomas.

You may qualify if:

  • Age 18 or older;
  • Newly treated or recurenced uterine sarcoma.

You may not qualify if:

  • Diagnosis of other malignancies within the past 5 years;
  • history of pelvic or vaginal radiation therapy;
  • Known high-grade lesions of the cervix and endometrium.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yan Li

Wuhan, Hubei, 430030, China

RECRUITING

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

May 21, 2023

First Posted

May 31, 2023

Study Start

March 1, 2023

Primary Completion

November 30, 2025

Study Completion

November 30, 2025

Last Updated

May 31, 2023

Record last verified: 2023-05

Locations

CN(1)